FDA 11月16日批准Biocon的Pebrilzo帕妥珠单抗生物类似药:为其在美第五个肿瘤生物类似药,美国上市最早2028年第三季度

印度 Biocon 有限公司11月16日宣布,美国食品药品管理局(FDA)已批准 Pebrilzo(pertuzumab-qcay)注射液,该药是原研药 Perjeta(帕妥珠单抗)的生物类似药。Pebrilzo 是一种单克隆抗体,通过阻断癌细胞上的 HER2 受体治疗 HER2 阳性乳腺癌。
获批适应症包括:与曲妥珠单抗和多西他赛联合,用于既往未接受过抗 HER2 治疗或化疗的 HER2 阳性转移性乳腺癌成人患者;以及与曲妥珠单抗和化疗联合,用于 HER2 阳性早期乳腺癌的新辅助与辅助治疗。
Biocon 表示,批准基于一份综合数据包,包括结构与功能分析表征、分析相似性研究与比较临床药代动力学数据,确认 Pebrilzo 与原研药高度相似,在质量、安全性、有效性与免疫原性方面没有临床意义上的差异。这是 Biocon 在美国获批的第五个肿瘤生物类似药。
批准不等于立即上市。Biocon 同时宣布已与 Genentech 达成全球和解与许可协议,Pebrilzo 在美国获得许可的最早商业上市时间为2028年第三季度。此前在2026年9月,欧洲药品管理局人用药品委员会已对该帕妥珠单抗生物类似药在欧洲以 Pebrilzo 品牌上市给出积极意见。
FDA Approves Biocon's Pebrilzo Pertuzumab Biosimilar on November 16: Its Fifth U.S. Oncology Biosimilar, With Earliest U.S. Launch in Q3 2028
Biocon Limited announced on November 16 that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay) injection, a biosimilar of the reference product Perjeta (pertuzumab). Pebrilzo is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells.
The approved indications include use with trastuzumab and docetaxel for adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease, and use with trastuzumab and chemotherapy in the neoadjuvant and adjuvant treatment of HER2-positive early-stage breast cancer.
Biocon said the approval was based on a comprehensive data package including structural and functional analytical characterization, analytical similarity studies and comparative clinical pharmacokinetic data, confirming that Pebrilzo is highly similar to the reference product with no clinically meaningful differences in quality, safety, efficacy and immunogenicity. It is Biocon's fifth oncology biosimilar approved in the United States.
Approval does not mean an immediate launch. Biocon also announced a global settlement and license agreement with Genentech that sets the earliest licensed U.S. commercial launch for Pebrilzo in the third quarter of calendar year 2028. In September 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use had already given a positive opinion for the pertuzumab biosimilar under the Pebrilzo brand in Europe.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:Mammogram with subtle cancer.jpg — Licensing: Public domain.
GSM Global · 本篇英文版 English edition of this story

